Cell-Free Fetal DNA Testing Market By Test Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Cell-Free Fetal DNA Testing Market
Cell-Free Fetal DNA Testing Market: By Test Type (Chromosome Number Abnormality Test, Paternal Inherited Disorder Test, Gender Test & Others) & By Geography(Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)
Report Code : HCR 0198
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
The cell-free fetal DNA (cffDNA) test is a new technology being used to assess the risk of a pregnant woman's developing baby (fetus) against any abnormalities such as chromosome disorder, like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), or Patau syndrome (trisomy 13). This new technology is being used as an alternative to currently available prenatal tests. It may be used to identify other rare conditions resulting from an extra chromosome or missing piece of chromosome (microdeletion). This new prenatal disorder testing technology is expected to be driven by major factors such as safe and low risk obstetric nature of this technology for prenatal testing coupled with increasing awareness about inherited disorders.

This report identifies the cell free fatal DNA testing market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to cell free fatal DNA testing market.

Cell-Free Fetal DNA Testing Market

Globally North America dominated the market for cell free fatal DNA testing in 2015 due to developed medical infrastructure and high occurrence of several disease related to cell free DNA testing. North America is expected to continue its domination and was followed by Europe and Asia-Pacific as the second and third largest markets respectively in 2015. However Asia-Pacific is expected to be the fastest growing market due to technological advancement and changing medical infrastructure in the major economies in the region along with increasing awareness about necessity prenatal testing.

This report on global cell free fatal DNA testing also covers different type of cell free fatal DNA testing available, and market size in various geographical regions.
  • On the basis of type of cell free fatal DNA testing this report classifies as follows covering all major types of cell free fatal DNA testing available in the market: Chromosome Number Abnormality Test, Paternal Inherited Disorder Test, Gender Test and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for cell free fatal DNA testing in each of the region.

Sample Companies Profiled in this Report are: 
  • The Fetal Medicine Centre
  • Apollo Path labs
  • Ariosa Diagnostics     
  • Sequenom Laboratories    
  • Laboratory Corp. of America Holdings
  • 10+
1. Cell-Free Fetal DNA Testing – Market Overview
2. Executive Summary
3. Cell-Free Fetal DNA Testing Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Cell-Free Fetal DNA Testing – Market Forces
   4.1. Drivers
      4.1.1. Increasing awareness about inherited diseases
      4.1.2. Safe and low risk obstetric procedures for prenatal testing
   4.2. Restraints
      4.2.1. High Cost
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Cell-Free Fetal DNA Testing Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Global Cell-Free Fetal DNA Testing Market, By Test Type
   6.1. Chromosome Number Abnormality Test
   6.2. Paternal Inherited Disorder Test
   6.3. Gender Test
   6.4. Others
7. Global Cell-Free Fetal DNA Testing Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Cell-Free Fetal DNA Testing – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles
   9.1. The Fetal Medicine Centre
      9.1.1. Introduction
      9.1.2. Financials
      9.1.3. Key Insights
      9.1.4. Key Strategy
      9.1.5. Product Portfolio
      9.1.6. SWOT Analysis
   9.2. Apollo Path labs
      9.2.1. Introduction
      9.2.2. Financials
      9.2.3. Key Insights
      9.2.4. Key Strategy
      9.2.5. Product Portfolio
      9.2.6. SWOT Analysis
   9.3. Ariosa Diagnostics     
      9.3.1. Introduction
      9.3.2. Financials
      9.3.3. Key Insights
      9.3.4. Key Strategy
      9.3.5. Product Portfolio
      9.3.6. SWOT Analysis
   9.4. Sequenom Laboratories    
      9.4.1. Introduction
      9.4.2. Financials
      9.4.3. Key Insights
      9.4.4. Key Strategy
      9.4.5. Product Portfolio
      9.4.6. SWOT Analysis
   9.5. Laboratory Corp. of America Holdings  
      9.5.1. Introduction
      9.5.2. Financials
      9.5.3. Key Insights
      9.5.4. Key Strategy
      9.5.5. Product Portfolio
      9.5.6. SWOT Analysis
   9.6. Personal Genome Diagnostics    
      9.6.1. Introduction
      9.6.2. Financials
      9.6.3. Key Insights
      9.6.4. Key Strategy
      9.6.5. Product Portfolio
      9.6.6. SWOT Analysis
   9.7. Premaitha Health 
      9.7.1. Introduction
      9.7.2. Financials
      9.7.3. Key Insights
      9.7.4. Key Strategy
      9.7.5. Product Portfolio
      9.7.6. SWOT Analysis
   9.8. Berry Genomics Co. Ltd     
      9.8.1. Introduction
      9.8.2. Financials
      9.8.3. Key Insights
      9.8.4. Key Strategy
      9.8.5. Product Portfolio
      9.8.6. SWOT Analysis
   9.9. Roche Holdings AG
      9.9.1. Introduction
      9.9.2. Financials
      9.9.3. Key Insights
      9.9.4. Key Strategy
      9.9.5. Product Portfolio
      9.9.6. SWOT Analysis
   9.10. Trovagene, Inc     
      9.10.1. Introduction
      9.10.2. Financials
      9.10.3. Key Insights
      9.10.4. Key Strategy
      9.10.5. Product Portfolio
      9.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll